Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells

Chen,Bo; Tan,Yaoxi; Liang,Yan; Li,Yan; Chen,Lei; Wu,Shuangshuang; Xu,Wei; Wang,Yan; Zhao,Weihong; Wu,Jianqing

doi:10.3892/ol.2016.5430

January-2017 Volume 13 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2017 Volume 13 Issue 1

Full Size Image

Article

Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells

Authors:
- Bo Chen
- Yaoxi Tan
- Yan Liang
- Yan Li
- Lei Chen
- Shuangshuang Wu
- Wei Xu
- Yan Wang
- Weihong Zhao
- Jianqing Wu
View Affiliations / Copyright

Affiliations: Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Pages: 423-428
|
Published online on: November 24, 2016

https://doi.org/10.3892/ol.2016.5430
Expand metrics +

Abstract

Period2 (Per2) is a key mammalian circadian clock protein, and additionally has a tumor suppressive function. The present study aimed to investigate its role in drug resistance in A549/cisplatin (DDP) lung adenocarcinoma cells. Per2 knockdown and overexpression in A549/DDP cells were used to compare cell proliferation (by MTT assay), apoptosis (active‑caspase 3 western blot) and clone forming assay. The activation of AKT/mechanistic target of rapamycin (mTOR) was investigated by a western blot assay. The Per2 expression level was decreased in A549/DDP cells compared with A549 cells. Per2 knockdown by short hairpin RNA protects A549/DDP cells from apoptosis, and promotes proliferation and migration. Per2 knockdown results in increased activation of the phosphoinositide 3‑kinase (PI3K)/AKT/mTOR signaling pathway. Overexpression of Per2 in A549/DDP cells may reduce the activity of the PI3K/AKT/mTOR signaling pathway, and promote apoptosis of A549 cells. The results of the present study suggest that Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells.

View Figures

View References

1	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
2	Deschesnes RG, Huot J, Valerie K and Landry J: Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol Biol Cell. 12:1569–1582. 2001. View Article : Google Scholar : PubMed/NCBI
3	Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D and Kharbanda S: Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J Biol Chem. 271:23775–23779. 1996. View Article : Google Scholar : PubMed/NCBI
4	Winograd-Katz SE and Levitzki A: Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 25:7381–7390. 2006. View Article : Google Scholar : PubMed/NCBI
5	Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene. 22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
6	Kandel ES and Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 253:210–229. 1999. View Article : Google Scholar : PubMed/NCBI
7	Wang M, Liu ZM, Li XC, Yao YT and Yin ZX: Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother. 25:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
8	Chi C, He ZF, Liu Y, Lin XM and Sun CC: Expression and clinical significance of circadian gene Per2 in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:129–131. 2013.(In Chinese). PubMed/NCBI
9	Liu B, Xu K, Jiang Y and Li X: Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. Int J Clin Exp Pathol. 7:7863–7871. 2014.PubMed/NCBI
10	Okabe T, Kumagai M, Nakajima Y, Shirotake S, Kodaira K, Oyama M, Ueno M and Ikeda M: The impact of HIF1α on the Per2 circadian rhythm in renal cancer cell lines. PLoS One. 9:e1096932014. View Article : Google Scholar : PubMed/NCBI
11	Zhao H, Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu XY, Han J, Liu KY, Liao JW, Xu RH and Zou QF: Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. Int J Clin Exp Pathol. 7:619–630. 2014.PubMed/NCBI
12	Esposito L, Conti D, Ailavajhala R, Khalil N and Giordano A: Lung Cancer: Are we up to the Challenge? Curr Genomics. 11:513–518. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fu L and Lee CC: The circadian clock: Pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003. View Article : Google Scholar : PubMed/NCBI
14	Yang X, He X, Yang Z and Jabbari E: Mammalian PER2 regulates AKT activation and DNA damage response. Biochem Cell Biol. 90:675–682. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ and Chang JG: Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 26:1241–1246. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles